-
2024-511684-28-00
4
2025-09-01
Potential malignancy in patients who received treatment with Autolus C
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-518276-32-00
4
2025-08-29
Locally advanced and unresectable Stage III non-small cell lung cancer
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-516412-17-00
5
2025-08-26
Developmental and Epileptic Encephalopathies (DEE)
-
2024-519331-42-00
5
2025-08-22
pMMR endometrial carcinoma
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2024-519928-24-00
4
2025-08-21
Myelodysplastic Syndrome
-
2024-520395-99-00
7
2025-08-12
Advanced solid tumors
-
2024-512132-29-00
4
2025-08-06
Metastatic castration-resistant prostate cancer
-
2024-515640-22-00
6
2025-08-06
polypoidal choroidal vasculopathy
-
2024-514440-86-00
4
2025-08-04
Relapse/Refractory Large B Cell Lymphoma
-
2024-515561-34-01
6
2025-08-04
Acute ischemic stroke with recent ingestion of direct oral anticoagula
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-512583-57-00
5
2025-07-30
HER2-positive locally advanced or metastatic gastric or gastroesophage
-
2024-519521-37-01
10
2025-07-30
Acute ischemic stroke
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2025-521340-37-00
5
2025-07-24
small cell lung cancer
-
2024-515098-93-00
5
2025-07-22
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML
-
2024-517568-48-00
5
2025-07-21
Delayed Graft Function after Kidney Transplantation
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-516162-11-00
5
2025-07-14
Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
-
2024-512981-33-00
4
2025-07-09
Metastatic Colorectal Cancer